All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2025-06-06.
From the record
Bolt Biotherapeutics, Inc.'s filings since 2017 show 3 warning events: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2025-06-06) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+101.6% a year over 6 filed years; profitable in 0 of 6.
From the record
Bolt Biotherapeutics, Inc.'s 6 filed years say what it did: revenue went from $231 thousand in fiscal 2020 to $8 million in fiscal 2025, up 101.6% a year; it rose in 4 of 5 years; the deepest fall was 2% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Bolt Biotherapeutics, Inc.'s shareholder treatment is put at 8.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 11% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -126%: lost 126¢ per shareholder dollar. Leverage 53%: owes 53¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Bolt Biotherapeutics, Inc. lost about 126 cents for every dollar of shareholders' money. Leverage: it owed about 53 cents per dollar of assets, and net share issuance: its share count shrank 2.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 43% of 315 in its family; net margin -433.7%.
From the record
Bolt Biotherapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $8 million in fiscal 2025 ranks in the bottom 38% by size; a net margin of -433.7% ranks in the bottom 39%; revenue growth of 10.3% a year over the last 3 filed years ranks in the top 48% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 37% of 315 in its family for leadership; chief executive since 2024.
From the record
Bolt Biotherapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Quinn, William P. (President, CEO and CFO, as filed), filing under that title since 2024-07-24, 2.3 years (bottom 26% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 4.9 years (bottom 34%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (top 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 47% of 273 in its family for room to expand.
From the record
Bolt Biotherapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $12 million against no long-term debt tagged leaves 20.6% of its assets as net cash, bottom 41% of its family; cash from operations less capital spending is -518.8% of revenue (bottom 34%); research spending of 370.8% of revenue (top 33%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 17% of 306 in its family for growth drivers.
From the record
Bolt Biotherapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 10.3% a year over the last three filed years against 101.6% over all 6, slowing (bottom 4% of its family); the newest year grew 0.1% (bottom 40%); research spending grew -26.9% a year (bottom 15%); capital spending grew -66.7% a year (bottom 9%) (its annual reports). Bolt Biotherapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 36% of 233 in its family for expectations against reality.
From the record
Bolt Biotherapeutics, Inc.'s newest year against its own record: revenue of $8 million in fiscal 2025 came in 13.6% below the $9 million its prior three years' pace pointed to (bottom 37% of its family); net income of $33 million against a prior three-year average of $73 million (top 29%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 17%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made